Enhanced COVID-19 Monoclonal Antibody Coming in 2023

AstraZeneca recently announced it accelerated the development of AZD5156, an investigational, long-acting monoclonal antibody (mAbs), and aims to make this new product available in the second half of 2023, subject to regulatory reviews.

On December 21, 2022, the company confirmed the first participant had been dosed in the SUPERNOVA Phase I/III trial of AZD5156 in pre-exposure prevention of COVID-19.

Iskra Reic, EVP, Vaccines and Immune Therapies, AstraZeneca, commented in a related press release, "EVUSHELD™ plays an important role around the world as the only option for pre-exposure prophylaxis for many immunocompromised patients who can't mount an adequate immune response to COVID-19 and are at high risk of poor outcomes from COVID-19."

"Our ambition with AZD5156 is to uphold our commitment to these vulnerable patients and provide an updated option that neutralizes all variants known to date in vitro and builds on the established safety and efficacy profile seen with EVUSHELD."

EVUSHELD is authorized in the U.S. for use under a temporary U.S. Food and Drug Administration (FDA) authorization for the pre-exposure prophylaxis of COVID-19 in certain adults and pediatric individuals.

As of December 22, 2022, EVUSHELD is not FDA Approved.

Other SARS-CoV-2 mAbs news is posted at CoronavorusToday.com/Antibodies.